Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer.
- Author:
Ji Won KIM
1
;
Youngil KOH
;
Dong Wan KIM
;
Yong Oon AHN
;
Tae Min KIM
;
Sae Won HAN
;
Do Youn OH
;
Se Hoon LEE
;
Seock Ah IM
;
Tae You KIM
;
Dae Seog HEO
;
Yung Jue BANG
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. kimdw@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Vascular endothelial growth factor;
Interleukin-1beta;
Transforming growth factor beta1;
Leukocytes;
Blood platelets;
Non-small cell lung carcinoma
- MeSH:
Blood Platelets;
Carcinoma, Non-Small-Cell Lung*;
Cytokines;
Disease-Free Survival;
Drug Therapy, Combination;
Female;
Humans;
Interleukin-1beta;
Interleukins;
Leukocytes;
Leukocytosis;
Male;
Multivariate Analysis;
Platelet Count;
Pneumonia;
Thrombocytosis;
Transforming Growth Factor beta1*;
Transforming Growth Factors;
Vascular Endothelial Growth Factor A*
- From:Cancer Research and Treatment
2013;45(4):325-333
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Vascular endothelial growth factor (VEGF)-A, VEGF165b, interleukin (IL)-1beta, and transforming growth factor (TGF)-beta1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated. MATERIALS AND METHODS: Using clinical data and baseline serum samples of 140 consecutive patients with advanced non-small cell lung cancer who received platinum-based combination chemotherapy, we investigated the association among serum cytokine levels, treatment outcomes, as well as leukocyte and platelet counts. RESULTS: The median age of patients was 64 years (range, 26 to 86 years). The male to female ratio was 104:36. High TGF-beta1 and IL-1beta levels were associated with shorter progression-free survival, and high VEGF-A and IL-1beta levels were associated with shorter overall survival in the univariate analysis. VEGF165b was not related to the treatment outcomes. Leukocytosis and thrombocytosis were associated with shorter overall survival. The multivariate analysis demonstrated that VEGF-A, IL-1beta, and leukocytosis were significant prognostic factors (p=0.0497, p=0.047, and p<0.001, respectively). Leukocytosis was not associated with recent pneumonia (p=0.937) and correlated with VEGF-A (p<0.001) and TGF-beta1 (p=0.020) levels. CONCLUSION: Serum VEGF-A, TGF-1beta, and IL-1beta levels, in addition to leukocyte and platelet counts, are shown to be associated with clinical outcomes. Leukocyte and platelet counts are correlated with serum VEGF-A and TGF-beta1 levels.
